Is Atea Pharmaceuticals Stock a Good Investment?
Atea Pharmaceuticals Investment Advice | AVIR |
- Examine Atea Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Atea Pharmaceuticals' leadership team and their track record. Good management can help Atea Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Atea Pharmaceuticals' business and its evolving consumer preferences.
- Compare Atea Pharmaceuticals' performance and market position to its competitors. Analyze how Atea Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Atea Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Atea Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Atea Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Atea Pharmaceuticals is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Atea Pharmaceuticals Stock
Researching Atea Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 69.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea Pharmaceuticals recorded a loss per share of 2.07. The entity last dividend was issued on the 9th of November 2012. The firm had 1:6 split on the 9th of November 2012.
To determine if Atea Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atea Pharmaceuticals' research are outlined below:
| Atea Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (135.96 M) with loss before overhead, payroll, taxes, and interest of (78.28 M). | |
| Atea Pharmaceuticals currently holds about 684.48 M in cash with (85.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Atea Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by institutions such as insurance companies |
Atea Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atea Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atea Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Atea Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 265.21 M.Basic technical analysis of Atea Stock
As of the 26th of February, Atea Pharmaceuticals shows the risk adjusted performance of (0.03), and Mean Deviation of 1.97. Atea Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atea Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Atea Pharmaceuticals is priced correctly, providing market reflects its regular price of 3.14 per share. Given that Atea Pharmaceuticals has information ratio of (0.05), we suggest you to validate Atea Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Atea Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atea Pharmaceuticals' Outstanding Corporate Bonds
Atea Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atea Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atea bonds can be classified according to their maturity, which is the date when Atea Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ATH 255 19 NOV 30 Corp BondUS04686E2U56 | View | |
| ATH 25 24 MAR 28 Corp BondUS04686E2Y78 | View | |
| ATH 345 15 MAY 52 Corp BondUS04686JAE10 | View | |
| ATH 395 25 MAY 51 Corp BondUS04686JAD37 | View | |
| US04686JAC53 Corp BondUS04686JAC53 | View | |
| ATHENE HLDG LTD Corp BondUS04686JAA97 | View | |
| ATHENE HLDG LTD Corp BondUS04686JAB70 | View | |
| ATH 665 01 FEB 33 Corp BondUS04686JAF84 | View |
Understand Atea Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Atea Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 1.97 | |||
| Coefficient Of Variation | (2,151) | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.47 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 12.68 | |||
| Value At Risk | (4.58) | |||
| Potential Upside | 5.05 | |||
| Skewness | (0.77) | |||
| Kurtosis | 2.66 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 1.97 | |||
| Coefficient Of Variation | (2,151) | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.47 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 12.68 | |||
| Value At Risk | (4.58) | |||
| Potential Upside | 5.05 | |||
| Skewness | (0.77) | |||
| Kurtosis | 2.66 |
Consider Atea Pharmaceuticals' intraday indicators
Atea Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atea Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Atea Pharmaceuticals time-series forecasting models is one of many Atea Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atea Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Atea Stock media impact
Far too much social signal, news, headlines, and media speculation about Atea Pharmaceuticals that are available to investors today. That information is available publicly through Atea media outlets and privately through word of mouth or via Atea internal channels. However, regardless of the origin, that massive amount of Atea data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Atea Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Atea Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Atea Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Atea Pharmaceuticals alpha.
Atea Pharmaceuticals Corporate Management
| CPA CPA | Exec Officer | Profile | |
| XiaoJian Zhou | Executive Development | Profile | |
| Jayanthi Wolf | Executive Affairs | Profile | |
| Wayne CPA | Executive Officer | Profile | |
| Ariyapadi Krishnaraj | Vice Marketing | Profile | |
| JeanPierre Sommadossi | Chairman, Founder | Profile | |
| John Vavricka | Chief Officer | Profile |
Already Invested in Atea Pharmaceuticals?
The danger of trading Atea Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atea Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atea Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atea Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.